# Electrophysiological study of the effect of cannabidiol on the dorsal raphe nucleus serotonergic neurons 

Erik Aostri (erik.aostri@ehu.eus) ${ }^{\text {a }}$, Joseba Pineda (joseba.pineda@ehu.eus) ${ }^{\text {a }}$, Aitziber Mendiguren (aitziber.mendiguren@ehu.eus) ${ }^{\text {a }}$.
${ }^{a}$ Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), E-48940 Leioa, Bizkaia, Spain

Keywords: cannabidiol, $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor, raphe nucleus, electrophysiology

## Graphical Abstract




#### Abstract

Cannabidiol (CBD) is the main non-psychoactive cannabinoid found in the Cannabis plant, which exerts several pharmacological effects including anxiolytic, antiemetic, antidepressant, antiepileptic and motor effects. In vivo evidence suggests that these pharmacological effects could be mediated by serotonergic $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptors. The dorsal raphe nucleus (DRN), which is the main serotonergic cluster in the brain, expresses $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor and plays a key role in the regulation of different functions such as mood and anxiety. To date, the nuclei involved in the action of CBD and the mechanisms by which it regulates $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor are still unknown. Therefore, the aim of this study was to characterize the effect of CBD on the firing rate of dorsal raphe $5-\mathrm{HT}$ neurons and $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor activation by single-unit extracellular electrophysiological recordings in vitro. Direct perfusion with CBD ( $30 \mu \mathrm{M}$ ) slightly but significantly reduced the firing activity of DRN 5HT cells. In order to study the effect of CBD on 5$\mathrm{HT}_{1 \mathrm{~A}}$ receptor activation, we applied the cannabinoid in the presence of two different $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor agonists: 8-OH DPAT ( 10 nM ) and ipsapirone ( 100 nM ). Application of 8-OH-DPAT or ipsapirone completely inhibited the firing activity of DRN 5-HT cells. However, in the presence of CBD $(30 \mu \mathrm{M})$ the inhibitory effects of 8-OH-DPAT and ipsapirone were reduced by $66 \%$ and $53 \%$,


|  | respectively. Finally, to discard the possible role of CBD as a competitive $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor antagonist, we administrated CBD once the cells had been totally inhibited with ipsapirone. Perfusion with CBD ( $30 \mu \mathrm{M}$ ) failed to recover the firing activity of inhibited $5-\mathrm{HT}$ cells, whereas $5-\mathrm{HT}_{1 \mathrm{~A}}$ antagonist WAY $100635(30 \mathrm{nM})$ recovered the firing rate of all 5-HT cells. In conclusion, these results suggest that CBD regulates the activity of $5-\mathrm{HT}_{1 \mathrm{~A}}$ receptor in an indirect manner since it does not displace the agonist from the binding site. |
| :---: | :---: |

## References

Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.

Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol. 2013 Mar;18(2):286-96

Mendiguren A, Pineda J. Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br J Pharmacol. 2009 Nov;158(6):1579-87

Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of $5-\mathrm{HT}(1 \mathrm{~A})$ somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012 Apr; 165(8):2620-34.

Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res. 2005 Aug;30(8):1037-43.

Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010 Jan;159(1):122-8.

